VCM
LENZ

Voleon Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Voleon Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,992
Closed -$274K – 944
2026
Q1 		$274K Buy
+29,992
New +$421K 0.01% 681
2025
Q4 		– Sell
-8,591
Closed -$400K – 1054
2025
Q3 		$400K Buy
+8,591
New +$316K 0.01% 643

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Voleon Capital Management's LENZ Position: Q2 2026 in Review

Voleon Capital Management sold out of LENZ Therapeutics (LENZ) in Q2 2026, closing a stake of 29,992 shares — an estimated $274K sold.

Voleon Capital Management first reported a position in LENZ in Q3 2025 and held it in 2 quarters. The position peaked at $400K in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Voleon Capital Management reported no remaining LENZ Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Voleon Capital Management sold 29,992 LENZ Therapeutics shares in Q2 2026, an estimated $274K.
  • Voleon Capital Management first reported a position in LENZ Therapeutics in Q3 2025 and held it in 2 quarters.
  • Voleon Capital Management's LENZ Therapeutics position peaked at $400K in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.